UFL1 (F5P6L) Rabbit mAb #96396
- WB
- IP
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 90 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Frozen) | 1:100 - 1:400 |
| Immunofluorescence (Immunocytochemistry) | 1:100 - 1:200 |
Storage
Protocol
Specificity / Sensitivity
UFL1 (F5P6L) Rabbit mAb recognizes endogenous levels of total UFL1 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human UFL1 protein.
Background
The ubiquitin-fold modifier 1 (UFM1) conjugation system (UFMylation) is a ubiquitin-like system that plays key roles in development and stress responses (1, reviewed in 2-4). Like ubiquitin, conjugation of UFM1 is a three-step enzymatic process involving a specific E1-activating enzyme (UBA5), an E2-conjugating enzyme (UFC1), and an E3-ligation enzyme (UFL1). Several substrates for UFMylation have been identified including DDRGK1, RPL26, p53, MRE11, histone H4, ASC1, CDK5RAP3, and CYB5R3 (5-12). Modification of these targets by UFM1 has direct effects on ER homeostasis, protein translation, and response to DNA damage. Notably, independent screens identified UFMylation as a key regulator of ER-phagy and autophagy (5,13,14). Aberrant UFMylation is associated with many pathological conditions, including cancer, diabetes, and inflammatory diseases (2-4).
- Tatsumi, K. et al. (2010) J Biol Chem 285, 5417-27.
- Gerakis, Y. et al. (2019) Trends Cell Biol 29, 974-986.
- Jiang, Q. et al. (2023) Front Endocrinol (Lausanne) 14, 1123124.
- Jing, Y. et al. (2022) Cancers (Basel) 14, 3501.
- Liu, J. et al. (2017) Nat Commun 8, 14186.
- Walczak, C.P. et al. (2019) Proc Natl Acad Sci USA 116, 1299-1308.
- Liu, J. et al. (2020) Nat Cell Biol 22, 1056-1063.
- Lee, L. et al. (2021) Sci Adv 7, eabc7371.
- Qin, B. et al. (2019) Nat Commun 10, 1242.
- Yoo, H.M. et al. (2014) Mol Cell 56, 261-274.
- Yang, R. et al. (2019) Development 146, dev169235. doi: 10.1242/dev.169235.
- Ishimura, R. et al. (2022) Nat Commun 13, 7857.
- Liang, J.R. et al. (2020) Cell 180, 1160-1177.e20.
- DeJesus, R. et al. (2016) Elife 5, e17290. doi: 10.7554/eLife.17290.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.